169 related articles for article (PubMed ID: 8059539)
1. Metabolic and pharmacokinetic studies following oral administration of 14C-famciclovir to healthy subjects.
Filer CW; Allen GD; Brown TA; Fowles SE; Hollis FJ; Mort EE; Prince WT; Ramji JV
Xenobiotica; 1994 Apr; 24(4):357-68. PubMed ID: 8059539
[TBL] [Abstract][Full Text] [Related]
2. Metabolic and pharmacokinetic studies following oral administration of famciclovir to the rat and dog.
Filer CW; Ramji JV; Allen GD; Brown TA; Fowles SE; Hollis FJ; Mort EE
Xenobiotica; 1995 May; 25(5):477-90. PubMed ID: 7571721
[TBL] [Abstract][Full Text] [Related]
3. Linear pharmacokinetics of penciclovir following administration of single oral doses of famciclovir 125, 250, 500 and 750 mg to healthy volunteers.
Pue MA; Pratt SK; Fairless AJ; Fowles S; Laroche J; Georgiou P; Prince W
J Antimicrob Chemother; 1994 Jan; 33(1):119-27. PubMed ID: 8157552
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of penciclovir in healthy cats following oral administration of famciclovir or intravenous infusion of penciclovir.
Thomasy SM; Whittem T; Bales JL; Ferrone M; Stanley SD; Maggs DJ
Am J Vet Res; 2012 Jul; 73(7):1092-9. PubMed ID: 22738064
[TBL] [Abstract][Full Text] [Related]
5. The clinical pharmacokinetics of famciclovir.
Gill KS; Wood MJ
Clin Pharmacokinet; 1996 Jul; 31(1):1-8. PubMed ID: 8827396
[TBL] [Abstract][Full Text] [Related]
6. Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-l-yl)guanine; penciclovir].
Vere Hodge RA; Sutton D; Boyd MR; Harnden MR; Jarvest RL
Antimicrob Agents Chemother; 1989 Oct; 33(10):1765-73. PubMed ID: 2589844
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of famciclovir in subjects with chronic hepatic disease.
Boike SC; Pue M; Audet PR; Freed MI; Fairless A; Ilson BE; Zariffa N; Jorkasky DK
J Clin Pharmacol; 1994 Dec; 34(12):1199-207. PubMed ID: 7738216
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of famciclovir and penciclovir in tears following oral administration of famciclovir to cats: a pilot study.
Thomasy SM; Covert JC; Stanley SD; Maggs DJ
Vet Ophthalmol; 2012 Sep; 15(5):299-306. PubMed ID: 22339892
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic modeling of penciclovir and BRL42359 in the plasma and tears of healthy cats to optimize dosage recommendations for oral administration of famciclovir.
Sebbag L; Thomasy SM; Woodward AP; Knych HK; Maggs DJ
Am J Vet Res; 2016 Aug; 77(8):833-45. PubMed ID: 27463546
[TBL] [Abstract][Full Text] [Related]
10. Lack of a pharmacokinetic interaction between oral famciclovir and allopurinol in healthy volunteers.
Fowles SE; Pratt SK; Laroche J; Prince WT
Eur J Clin Pharmacol; 1994; 46(4):355-9. PubMed ID: 7957522
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and safety of penciclovir following oral administration of famciclovir to cats.
Thomasy SM; Maggs DJ; Moulin NK; Stanley SD
Am J Vet Res; 2007 Nov; 68(11):1252-8. PubMed ID: 17975982
[TBL] [Abstract][Full Text] [Related]
12. Use of isotopically chiral [4'-13C]famciclovir and 13C NMR to identify the chiral monoacetylated intermediates in the conversion of famciclovir to penciclovir by human intestinal wall extract.
Vere Hodge RA; Darlison SJ; Readshaw SA
Chirality; 1993; 5(8):577-82. PubMed ID: 8305284
[TBL] [Abstract][Full Text] [Related]
13. Evidence that famciclovir (BRL 42810) and its associated metabolites do not inhibit the 6 beta-hydroxylation of testosterone in human liver microsomes.
Harrell AW; Wheeler SM; Pennick M; Clarke SE; Chenery RJ
Drug Metab Dispos; 1993; 21(1):18-23. PubMed ID: 8095215
[TBL] [Abstract][Full Text] [Related]
14. Intraocular penetration of penciclovir after oral administration of famciclovir: a population pharmacokinetic model.
Schenkel F; Csajka C; Baglivo E; Kondo-Oestreicher M; Dayer P; Gex-Fabry M; Daali Y
J Antimicrob Chemother; 2013 Jul; 68(7):1635-41. PubMed ID: 23539240
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of penciclovir after oral administration of its prodrug famciclovir to horses.
Tsujimura K; Yamada M; Nagata S; Yamanaka T; Nemoto M; Kondo T; Kurosawa M; Matsumura T
J Vet Med Sci; 2010 Mar; 72(3):357-61. PubMed ID: 19959884
[TBL] [Abstract][Full Text] [Related]
16. Role of aldehyde oxidase in the in vitro conversion of famciclovir to penciclovir in human liver.
Clarke SE; Harrell AW; Chenery RJ
Drug Metab Dispos; 1995 Feb; 23(2):251-4. PubMed ID: 7736920
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of famciclovir in subjects with varying degrees of renal impairment.
Boike SC; Pue MA; Freed MI; Audet PR; Fairless A; Ilson BE; Zariffa N; Jorkasky DK
Clin Pharmacol Ther; 1994 Apr; 55(4):418-26. PubMed ID: 8162668
[TBL] [Abstract][Full Text] [Related]
18. Estimates of the pharmacokinetics of famciclovir and its active metabolite penciclovir in young Asian elephants (Elephas maximus).
Brock AP; Isaza R; Hunter RP; Richman LK; Montali RJ; Schmitt DL; Koch DE; Lindsay WA
Am J Vet Res; 2012 Dec; 73(12):1996-2000. PubMed ID: 23176429
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic studies of 2-amino-9-(3-acetoxymethyl-4-isopropoxycarbonyl-oxybut-1-yl)purine, an oral prodrug for the antiviral agent penciclovir.
Choi WS; Im GJ; Kim DK; Kim TK; Jung I; Kim TS; Lee SJ; Lee N; Kim YW; Kim JS; Chang K
Drug Metab Dispos; 2001 Jul; 29(7):945-9. PubMed ID: 11408358
[TBL] [Abstract][Full Text] [Related]
20. Vitreous penetration of orally administered famciclovir.
Chong DY; Johnson MW; Huynh TH; Hall EF; Comer GM; Fish DN
Am J Ophthalmol; 2009 Jul; 148(1):38-42.e1. PubMed ID: 19375688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]